Panettiere F J, Jones S E, Oishi N, Eyre H J, O'Bryan R M, Andes W A, Taylor S A, Grozea P N
Med Pediatr Oncol. 1986;14(2):78-80. doi: 10.1002/mpo.2950140204.
Because "the standard" chemotherapy for advanced gastric adenocarcinoma, the FAM combination of 5-fluorouracil, adriamycin, and mitomycin, is only minimally effective, there is a clear need for other choices. Therefore, the Southwest Oncology Group tested the new adriamycin analog, bisantrene, hoping that it might be more effective than the "parent drug." Twenty-six patients with gastric adenocarcinoma were treated on a program of every-3-week 2-hour bisantrene infusions. The starting dose was 260 mg/m2 (208 if poor risk), with subsequent doses based on prior toxicity. The regimen caused sufficient toxicity (especially local phlebitis with pain and swelling) to assure an adequate test. One person (3.8% of eligible patients) experienced a clinically useful 3-month response. He had previously had progressive disease on FAM. Nevertheless, we conclude that bisantrene is not an addition to the small list of drugs useful in the management of gastric adenocarcinoma.
由于晚期胃腺癌的“标准”化疗方案，即由5-氟尿嘧啶、阿霉素和丝裂霉素组成的FAM联合方案疗效甚微，显然需要其他选择。因此，西南肿瘤协作组对新的阿霉素类似物比生群进行了试验，希望它可能比“母药”更有效。26例胃腺癌患者接受了每3周一次、每次2小时静脉输注比生群的治疗方案。起始剂量为260mg/m²（如果风险较高则为208mg/m²），后续剂量根据先前的毒性情况调整。该方案产生了足够的毒性（尤其是伴有疼痛和肿胀的局部静脉炎），以确保进行充分的试验。有1人（占符合条件患者的3.8%）出现了持续3个月的临床有效反应。他之前接受FAM方案治疗时病情进展。然而，我们得出结论，比生群并非可用于治疗胃腺癌的少数有效药物之一。
